Eccentric Exercise Rehabilitation After Myocardial Infarction
ECCENTRIC-MI
Effects of Two-Week Eccentric Exercise-Based Cardiac Rehabilitation on Myokines, Exerkines, and Physical Function in Patients After Myocardial Infarction
2 other identifiers
interventional
60
1 country
1
Brief Summary
This clinical trial will evaluate a two-week eccentric exercise program conducted as part of comprehensive cardiac rehabilitation in patients after a heart attack (myocardial infarction). Eccentric exercise involves muscle contractions while the muscles are lengthening and may allow the muscles to work at a relatively high load with a lower cardiovascular and metabolic demand than traditional exercise. The main aim of the study is to determine whether eccentric exercise affects blood levels of proteins released or regulated in response to physical activity, including musclin, interleukin-6, and myostatin. The study will also evaluate whether the program improves physical performance and functional capacity. Participants will complete eccentric cycling exercise on a semi-recumbent cycle ergometer during a two-week cardiac rehabilitation program. Blood samples and physical-function measurements will be collected before and after the intervention.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jul 2026
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 22, 2026
CompletedStudy Start
First participant enrolled
July 22, 2026
CompletedFirst Posted
Study publicly available on registry
July 27, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 21, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 21, 2028
July 27, 2026
July 1, 2026
12 months
July 22, 2026
July 22, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Change From Baseline in Serum Musclin Concentration
Serum musclin concentration will be measured in fasting venous blood samples using an enzyme-linked immunosorbent assay (ELISA). The outcome will be calculated as the concentration measured after the intervention minus the baseline concentration and reported in ng/mL.
Baseline and after completion of the 2-week inpatient cardiac rehabilitation program
Change From Baseline in Serum Myostatin Concentration
Serum myostatin concentration will be measured in fasting venous blood samples using an enzyme-linked immunosorbent assay (ELISA). The outcome will be calculated as the concentration measured after the intervention minus the baseline concentration.
Baseline and after completion of the 2-week inpatient cardiac rehabilitation program
Change From Baseline in Serum Interleukin-6 Concentration
Serum interleukin-6 concentration will be measured in fasting venous blood samples using an enzyme-linked immunosorbent assay (ELISA). The outcome will be calculated as the concentration measured after the intervention minus the baseline concentration.
Baseline and after completion of the 2-week inpatient cardiac rehabilitation program
Secondary Outcomes (4)
Change From Baseline in Six-Minute Walk Distance
Baseline, before initiation of the inpatient cardiac rehabilitation program, and after completion of the 2-week intervention
30-Second Chair-Stand Test
Baseline, before initiation of the inpatient cardiac rehabilitation program, and after completion of the 2-week intervention
Change From Baseline in Kinesiophobia Assessed Using the Tampa Scale for Kinesiophobia Heart
Baseline, before initiation of the inpatient cardiac rehabilitation program, and after completion of the 2-week intervention
Change From Baseline in Peak Force During the Isometric Mid-Thigh Pull Test
Baseline, before initiation of the inpatient cardiac rehabilitation program, and after completion of the 2-week intervention
Other Outcomes (1)
Change From Baseline in the Kynurenine-to-Tryptophan Ratio
Baseline, before initiation of stage I inpatient cardiac rehabilitation, and after completion of the 2-week intervention
Study Arms (2)
Standard Cardiac Rehabilitation
ACTIVE COMPARATORStandard stage I inpatient cardiac rehabilitation provided after myocardial infarction and individualized according to each participant's clinical condition and exercise capacity. The program includes standard kinesitherapy and exercise-based rehabilitation procedures.
Standard Cardiac Rehabilitation Plus Eccentric Cycling
EXPERIMENTALSupervised eccentric cycling exercise performed on a motor-driven semi-recumbent cycle ergometer in addition to standard inpatient cardiac rehabilitation. Sessions will last 10 to 30 minutes, with progressive adaptation during the first five sessions. Exercise workload will be individualized according to baseline exercise capacity. Perceived exertion and muscle soreness will be monitored during each session.
Interventions
Standard stage I inpatient cardiac rehabilitation provided after myocardial infarction and individualized according to each participant's clinical condition and exercise capacity. The program includes standard kinesitherapy and exercise-based rehabilitation procedures.
Supervised eccentric cycling exercise performed on a motor-driven semi-recumbent cycle ergometer in addition to standard inpatient cardiac rehabilitation. Sessions will last 10 to 30 minutes, with progressive adaptation during the first five sessions. Exercise workload will be individualized according to baseline exercise capacity. Perceived exertion and muscle soreness will be monitored during each session.
Eligibility Criteria
You may qualify if:
- Documented history of myocardial infarction confirmed by medical records.
- Qualification for stage I comprehensive inpatient cardiac rehabilitation.
- Clinically stable condition allowing participation in exercise-based cardiac rehabilitation.
- New York Heart Association functional class I or II.
- Moderate or good exercise tolerance, defined as an exercise capacity of at least 5 metabolic equivalents, assessed during an exercise test.
- No cardiovascular contraindications to exercise testing or participation in exercise-based cardiac rehabilitation.
- Ability to understand the study procedures and follow the instructions provided by the study personnel.
- Provision of written informed consent to participate in the study.
You may not qualify if:
- Any contraindication to exercise-based cardiac rehabilitation or exercise testing.
- Acute myocardial infarction within the first 4 days before planned initiation of exercise rehabilitation.
- Unstable angina.
- Significant left main coronary artery stenosis considered a contraindication to exercise by the treating cardiologist.
- Symptomatic cardiac arrhythmias.
- Symptomatic severe aortic stenosis.
- Decompensated heart failure.
- Acute pulmonary embolism or pulmonary infarction.
- Deep vein thrombosis.
- Recent or mobile intracardiac thrombus.
- Acute myocarditis, endocarditis, or pericarditis.
- Aortic dissection.
- Symptomatic acquired second- or third-degree atrioventricular block without appropriate cardiac pacing.
- Poorly controlled arterial hypertension.
- Recent stroke or transient cerebral ischemic event.
- +3 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Florian Ceynowa Specialist Hospital in Wejherowo
Wejherowo, Pomeranian Voivodeship, 84-200, Poland
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Masking Details
- Participants, care providers, and investigators are aware of group assignment. Laboratory personnel analyzing coded blood samples are blinded to treatment allocation.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 22, 2026
First Posted
July 27, 2026
Study Start
July 22, 2026
Primary Completion (Estimated)
July 21, 2027
Study Completion (Estimated)
July 21, 2028
Last Updated
July 27, 2026
Record last verified: 2026-07
Data Sharing
- IPD Sharing
- Will not share
There is currently no plan to make de-identified individual participant data available to other researchers. Study findings will be reported in aggregate form in scientific publications and presentations.